

27 April 2016

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement – Intended Move to ASX

iQnovate Limited (NSX: IQN,OTC:IQNDY) Announces that it intends to list its shares on the Australian Securities Exchange (ASX). This listing on Australia’s premier stock exchange is intended to enhance the company’s stock liquidity and to address a considerably broader investor base.

Dr George Syrmalis, iQnovate’s Executive Chairman and CEO, said: “Our company’s growth rate is accelerating and in order to sustain this growth and successfully execute multiple global clinical programs, its imperative that IQN is listed on an exchange that has an international customer base, facilitates investor transactions and is able to provide a highly liquid market for the company’s securities. The ASX is a globally competitive market and is one of the worlds top 10 exchanges by market capitalization. We contemplate that by this transition IQN shares will be better exposed to institutional and international investors”.

A final timetable for the change in listing and details about the process will be released to the market in due course after approval by the company’s shareholders.

In accordance with the NSX listing rules, the company is obliged to provide at least 90 days’ notice to NSX of its intention to withdraw its listing and to also seek the approval of its shareholders by the requisite majority.

For and on behalf of the Board.



Kelvin Boateng
Company Secretary
iQnovate Ltd

For further information:

Investors

iQnovate Investor Relations Team

Email: investor.relations@iqnovate.com

Phone: +61 2 8239 5400

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQnovate Ltd

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.